Evolution of melanoma cross-resistance to CD8⁺ T cells and MAPK inhibition in the course of BRAFi treatment

References

• Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Eng J Med. 2011;364(26):2507–16. doi:10.1056/NEJMoa1103782. PMID:21639808.
   PubMed Web of Science ®Google Scholar
• Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Attar N, Sazegar H, Chodon T, Nelson SF, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973–7. doi:10.1038/nature09626. PMID:21107323.
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Eng J Med. 2014;371(20):1877–88. doi:10.1056/NEJMoa1406037. PMID:25265492.
   PubMed Web of Science ®Google Scholar
• Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Eng J Med. 2014;371(20):1867–76. doi:10.1056/NEJMoa1408868. PMID:25265494.
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Eng J Med. 2015;372(1):30–9. doi:10.1056/NEJMoa1412690. PMID:25399551.
   PubMed Web of Science ®Google Scholar
• Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, et al. Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving Dabrafenib combined with Trametinib. J Clin Oncol. 2016;34(8):871–8. doi:10.1200/JCO.2015.62.9345. PMID:26811525.
   PubMed Web of Science ®Google Scholar
• Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19(5):1225–31. doi:10.1158/1078-0432.CCR-12-1630. PMID:23307859.
   PubMed Web of Science ®Google Scholar
• Cooper ZA, Frederick DT, Juneja VR, Sullivan RJ, Lawrence DP, Piris A, Sharpe AH, Fisher DE, Flaherty KT, Wargo JA. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology. 2013;2(10):e26615. doi:10.4161/onci.26615. PMID:24251082.
   PubMed Web of Science ®Google Scholar
• Donia M, Fagone P, Nicoletti F, Andersen RS, Hogdall E, Straten PT, Andersen MH, Svane IM. BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology. 2012;1(9):1476–83. doi:10.4161/onci.21940. PMID:23264894.
   PubMed Web of Science ®Google Scholar
• Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, Kefford RF, Hersey P, Scolyer RA. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012;18(5):1386–94. doi:10.1158/1078-0432.CCR-11-2479. PMID:22156613.
   PubMed Web of Science ®Google Scholar
• Sabbatino F, Wang Y, Scognamiglio G, Favoino E, Feldman SA, Villani V, et al. Antitumor activity of BRAF inhibitor and IFNalpha combination in BRAF-mutant Melanoma. J Natl Cancer Institute. 2016;108(7). doi:10.1093/jnci/djv435. PMID:26851802.
   PubMedGoogle Scholar
• Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010;70(13):5213–9. doi:10.1158/0008-5472.CAN-10-0118. PMID:20551059.
   PubMed Web of Science ®Google Scholar
• Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW, et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014;2(7):643–54. doi:10.1158/2326-6066.CIR-13-0215. PMID:24903021.
   PubMed Web of Science ®Google Scholar
• Kakavand H, Wilmott JS, Menzies AM, Vilain R, Haydu LE, Yearley JH, Thompson JF, Kefford RF, Hersey P, Long GV, et al. PD-L1 Expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor-treated melanoma patients. Clin Cancer Res. 2015;21(14):3140–8. doi:10.1158/1078-0432.CCR-14-2023. PMID:25609064.
   PubMed Web of Science ®Google Scholar
• Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest. 2013;123(3):1371–81. doi:10.1172/JCI66236. PMID:23454771.
   PubMed Web of Science ®Google Scholar
• Koya RC, Mok S, Otte N, Blacketor KJ, Comin-Anduix B, Tumeh PC, Minasyan A, Graham NA, Graeber TG, Chodon T, et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 2012;72(16):3928–37. doi:10.1158/0008-5472.CAN-11-2837. PMID:22693252.
   PubMed Web of Science ®Google Scholar
• Deken MA, Gadiot J, Jordanova ES, Lacroix R, van Gool M, Kroon P, Pineda C, Geukes Foppen MH, Scolyer R, Song JY, et al. Targeting the MAPK and PI3 K pathways in combination with PD1 blockade in melanoma. Oncoimmunology. 2016;5(12):e1238557. doi:10.1080/2162402X.2016.1238557. PMID:28123875.
   PubMed Web of Science ®Google Scholar
• Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, Moriceau G, Hong A, Dahlman KB, Johnson DB, et al. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell. 2015;162(6):1271–85. doi:10.1016/j.cell.2015.07.061. PMID:26359985.
   PubMed Web of Science ®Google Scholar
• Haferkamp S, Borst A, Adam C, Becker TM, Motschenbacher S, Windhovel S, et al. Vemurafenib induces senescence features in melanoma cells. The J Invest Dermatol. 2013;133(6):1601–9. doi:10.1038/jid.2013.6. PMID:23321925.
   PubMed Web of Science ®Google Scholar
• Schrors B, Lubcke S, Lennerz V, Fatho M, Bicker A, Wolfel C, Derigs P, Hankeln T, Schadendorf D, Paschen A, et al. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model. Oncotarget. 2017;8(17):28312–27. doi:10.18632/oncotarget.16048. PMID:28423700.
   PubMedGoogle Scholar
• Yarchoan M, Johnson BA, Lutz ER 3rd, Laheru DA, Jaffee EM. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 2017;17(4):209–22. doi:10.1038/nrc.2016.154. PMID:28233802.
   PubMed Web of Science ®Google Scholar
• Keller M, Ebstein F, Burger E, Textoris-Taube K, Gorny X, Urban S, Zhao F, Dannenberg T, Sucker A, Keller C, et al. The proteasome immunosubunits, PA28 and ER-aminopeptidase 1 protect melanoma cells from efficient MART-126-35 -specific T-cell recognition. Eur J Immunol. 2015;45(12):3257–68. doi:10.1002/eji.201445243. PMID:26399368.
   PubMed Web of Science ®Google Scholar
• Song C, Piva M, Sun L, Hong A, Moriceau G, Kong X, Zhang H, Lomeli S, Qian J, Yu CC, et al. Recurrent tumor cell-intrinsic and -extrinsic alterations during MAPKi-induced melanoma regression and early adaptation. Cancer Discov. 2017;7(11):1248–65. doi:10.1158/2159-8290.CD-17-0401. PMID:28864476.
   PubMed Web of Science ®Google Scholar
• Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013;19(2):393–403. doi:10.1158/1078-0432.CCR-12-1626. PMID:23204132.
   PubMed Web of Science ®Google Scholar
• Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Pinheiro EM, Koya RC, Graeber TG, Comin-Anduix B, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Translational Med. 2015;7(279):279ra41. doi:10.1126/scitranslmed.aaa4691. PMID:25787767.
   PubMed Web of Science ®Google Scholar
• Deniger DC, Kwong ML, Pasetto A, Dudley ME, Wunderlich JR, Langhan MM, Lee CR, Rosenberg SA. A pilot trial of the combination of vemurafenib with adoptive cell therapy in patients with metastatic melanoma. Clin Cancer Res. 2017;23(2):351–62. doi:10.1158/1078-0432.CCR-16-0906. PMID:28093487.
   PubMed Web of Science ®Google Scholar
• Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, Gunturi A, Flaherty KT, Hodi FS, Kefford R, et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer. 2014;120(11):1695–701. doi:10.1002/cncr.28620. PMID:24577748.
   PubMed Web of Science ®Google Scholar
• Ebstein F, Lange N, Urban S, Seifert U, Kruger E, Kloetzel PM. Maturation of human dendritic cells is accompanied by functional remodelling of the ubiquitin-proteasome system. Int J Biochem Cell Biol. 2009;41(5):1205–15. doi:10.1016/j.biocel.2008.10.023. PMID:19028597.
   PubMed Web of Science ®Google Scholar
• Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995;92(20):9363–7. doi:10.1073/pnas.92.20.9363. PMID:7568133.
   PubMed Web of Science ®Google Scholar